A Phase 1b Study of ALRN-6924 in Combination With Paclitaxel in Wild-Type TP53 Advanced or Metastatic Solid Tumors Including Estrogen-Receptor Positive Breast Cancer
Latest Information Update: 02 May 2025
At a glance
- Drugs ALRN 6924 (Primary) ; Paclitaxel (Primary)
- Indications Advanced breast cancer; Solid tumours
- Focus Adverse reactions
Most Recent Events
- 25 Apr 2025 Planned End Date changed from 30 Apr 2025 to 26 Jul 2025.
- 25 Apr 2025 Planned primary completion date changed from 30 Apr 2025 to 26 Jul 2025.
- 06 Oct 2023 Planned End Date changed from 26 Jul 2023 to 30 Apr 2025.